Geode Capital Management LLC Sells 1,931 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Geode Capital Management LLC reduced its stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 0.6% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 321,977 shares of the medical research company's stock after selling 1,931 shares during the period. Geode Capital Management LLC owned about 1.15% of Bio-Rad Laboratories worth $105,586,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Venturi Wealth Management LLC lifted its holdings in Bio-Rad Laboratories by 2,175.0% during the fourth quarter. Venturi Wealth Management LLC now owns 91 shares of the medical research company's stock valued at $30,000 after purchasing an additional 87 shares during the last quarter. Picton Mahoney Asset Management boosted its holdings in Bio-Rad Laboratories by 55.6% in the 4th quarter. Picton Mahoney Asset Management now owns 98 shares of the medical research company's stock worth $32,000 after buying an additional 35 shares during the period. Asset Planning Inc bought a new position in Bio-Rad Laboratories in the 4th quarter worth approximately $33,000. UMB Bank n.a. raised its holdings in Bio-Rad Laboratories by 41.6% during the 4th quarter. UMB Bank n.a. now owns 109 shares of the medical research company's stock valued at $36,000 after acquiring an additional 32 shares during the period. Finally, Cape Investment Advisory Inc. bought a new stake in Bio-Rad Laboratories during the 4th quarter valued at $38,000. 65.24% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on BIO shares. StockNews.com cut Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a research report on Monday, February 17th. Wells Fargo & Company decreased their price target on Bio-Rad Laboratories from $360.00 to $345.00 and set an "equal weight" rating on the stock in a research report on Wednesday, February 12th. Finally, Royal Bank of Canada restated an "outperform" rating and issued a $481.00 price objective on shares of Bio-Rad Laboratories in a research report on Tuesday, January 14th. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $395.20.

Bio-Rad Laboratories Price Performance

Shares of BIO traded down $1.72 during trading hours on Tuesday, reaching $247.90. 56,483 shares of the company's stock traded hands, compared to its average volume of 316,301. Bio-Rad Laboratories, Inc. has a 12 month low of $215.38 and a 12 month high of $387.99. The company has a current ratio of 6.48, a quick ratio of 4.85 and a debt-to-equity ratio of 0.18. The stock has a market cap of $6.94 billion, a PE ratio of -3.81 and a beta of 1.12. The firm's 50 day simple moving average is $262.86 and its 200-day simple moving average is $314.11.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last released its quarterly earnings results on Thursday, February 13th. The medical research company reported $2.90 EPS for the quarter, topping analysts' consensus estimates of $2.86 by $0.04. Bio-Rad Laboratories had a negative net margin of 71.86% and a positive return on equity of 3.90%. Equities analysts expect that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current year.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.